The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans

Michael W. Weiner, Paul S. Aisen, Clifford R. Jack, William J. Jagust, John Q. Trojanowski, Leslie Shaw, Andrew Saykin, John C. Morris, Nigel Cairns, Laurel A. Beckett, Arthur Toga, Robert Green, Sarah Walter, Holly Soares, Peter Snyder, Eric Siemers, William Potter, Patricia E. Cole, Mark Schmidt

Research output: Contribution to journalArticle

271 Citations (Scopus)

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.

Original languageEnglish
JournalAlzheimer's and Dementia
Volume6
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Neuroimaging
Alzheimer Disease
Cerebrospinal Fluid
Atrophy
Brain
Biomarkers
Korea
Amyloid
Cognition
Japan
Clinical Trials
Therapeutics
Research
Cognitive Dysfunction

Keywords

  • ADNI
  • Alzheimer's disease
  • Amyloid
  • Memory
  • MRI
  • PET
  • Tau

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology
  • Medicine(all)

Cite this

Weiner, M. W., Aisen, P. S., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Shaw, L., ... Schmidt, M. (2010). The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. Alzheimer's and Dementia, 6(3). https://doi.org/10.1016/j.jalz.2010.03.007

The Alzheimer's Disease Neuroimaging Initiative : Progress report and future plans. / Weiner, Michael W.; Aisen, Paul S.; Jack, Clifford R.; Jagust, William J.; Trojanowski, John Q.; Shaw, Leslie; Saykin, Andrew; Morris, John C.; Cairns, Nigel; Beckett, Laurel A.; Toga, Arthur; Green, Robert; Walter, Sarah; Soares, Holly; Snyder, Peter; Siemers, Eric; Potter, William; Cole, Patricia E.; Schmidt, Mark.

In: Alzheimer's and Dementia, Vol. 6, No. 3, 05.2010.

Research output: Contribution to journalArticle

Weiner, MW, Aisen, PS, Jack, CR, Jagust, WJ, Trojanowski, JQ, Shaw, L, Saykin, A, Morris, JC, Cairns, N, Beckett, LA, Toga, A, Green, R, Walter, S, Soares, H, Snyder, P, Siemers, E, Potter, W, Cole, PE & Schmidt, M 2010, 'The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans', Alzheimer's and Dementia, vol. 6, no. 3. https://doi.org/10.1016/j.jalz.2010.03.007
Weiner, Michael W. ; Aisen, Paul S. ; Jack, Clifford R. ; Jagust, William J. ; Trojanowski, John Q. ; Shaw, Leslie ; Saykin, Andrew ; Morris, John C. ; Cairns, Nigel ; Beckett, Laurel A. ; Toga, Arthur ; Green, Robert ; Walter, Sarah ; Soares, Holly ; Snyder, Peter ; Siemers, Eric ; Potter, William ; Cole, Patricia E. ; Schmidt, Mark. / The Alzheimer's Disease Neuroimaging Initiative : Progress report and future plans. In: Alzheimer's and Dementia. 2010 ; Vol. 6, No. 3.
@article{d9a70d503ae34c9a99a6d191e10809d2,
title = "The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans",
abstract = "The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.",
keywords = "ADNI, Alzheimer's disease, Amyloid, Memory, MRI, PET, Tau",
author = "Weiner, {Michael W.} and Aisen, {Paul S.} and Jack, {Clifford R.} and Jagust, {William J.} and Trojanowski, {John Q.} and Leslie Shaw and Andrew Saykin and Morris, {John C.} and Nigel Cairns and Beckett, {Laurel A.} and Arthur Toga and Robert Green and Sarah Walter and Holly Soares and Peter Snyder and Eric Siemers and William Potter and Cole, {Patricia E.} and Mark Schmidt",
year = "2010",
month = "5",
doi = "10.1016/j.jalz.2010.03.007",
language = "English",
volume = "6",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The Alzheimer's Disease Neuroimaging Initiative

T2 - Progress report and future plans

AU - Weiner, Michael W.

AU - Aisen, Paul S.

AU - Jack, Clifford R.

AU - Jagust, William J.

AU - Trojanowski, John Q.

AU - Shaw, Leslie

AU - Saykin, Andrew

AU - Morris, John C.

AU - Cairns, Nigel

AU - Beckett, Laurel A.

AU - Toga, Arthur

AU - Green, Robert

AU - Walter, Sarah

AU - Soares, Holly

AU - Snyder, Peter

AU - Siemers, Eric

AU - Potter, William

AU - Cole, Patricia E.

AU - Schmidt, Mark

PY - 2010/5

Y1 - 2010/5

N2 - The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.

AB - The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.

KW - ADNI

KW - Alzheimer's disease

KW - Amyloid

KW - Memory

KW - MRI

KW - PET

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=77955474351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955474351&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2010.03.007

DO - 10.1016/j.jalz.2010.03.007

M3 - Article

C2 - 20451868

AN - SCOPUS:77955474351

VL - 6

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -